| Assay ID | Title | Year | Journal | Article |
|---|
| AID1402865 | Inhibition of human cathepsin K kinase activity assessed as normalized bradykinin equivalents ratio at 1 uM pre-incubated for 15 mins before bradykinin substrate addition by competitive enzyme immunoassay (Rvb = <0.5%) | 2018 | European journal of medicinal chemistry, Jan-20, Volume: 144 | Substrate-derived triazolo- and azapeptides as inhibitors of cathepsins K and S. |
| AID1712998 | Inhibition of cathepsin B (unknown origin) using RR-AMC as substrate preincubated for 30 mins followed by substrate addition and further incubated for 30 mins under shaking condition by fluorescence assay | 2016 | European journal of medicinal chemistry, Oct-04, Volume: 121 | Neuroprotective effect of synthetic chalcone derivatives as competitive dual inhibitors against μ-calpain and cathepsin B through the downregulation of tau phosphorylation and insoluble Aβ peptide formation. |
| AID350737 | Inhibition of human liver cathepsin B after 30 mins by fluorometric end-point assay | 2009 | Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
| Identification of 3-acetyl-2-aminoquinolin-4-one as a novel, nonpeptidic scaffold for specific calpain inhibitory activity. |
| AID1402866 | Inhibition of human cathepsin K kinase activity assessed as normalized bradykinin equivalents ratio at 1 uM pre-incubated for 15 mins before kallidin substrate addition by competitive enzyme immunoassay (Rvb = <0.5%) | 2018 | European journal of medicinal chemistry, Jan-20, Volume: 144 | Substrate-derived triazolo- and azapeptides as inhibitors of cathepsins K and S. |
| AID1713010 | Neuroprotective activity in human SH-SY5Y cells assessed as reduction in GOx-induced PARP cleavage at 20 uM pretreated with GOx for 4 hrs followed by compound treatment by Western blot analysis | 2016 | European journal of medicinal chemistry, Oct-04, Volume: 121 | Neuroprotective effect of synthetic chalcone derivatives as competitive dual inhibitors against μ-calpain and cathepsin B through the downregulation of tau phosphorylation and insoluble Aβ peptide formation. |
| AID1372431 | Inhibition of Cathepsin-B (unknown origin) at 5 uM preincubated for 15 mins followed by Z-Arg-Arg-AMC addition measured after 30 mins by fluorescence assay relative to control | 2018 | Bioorganic & medicinal chemistry, 01-01, Volume: 26, Issue:1
| Synthesis and biological evaluation of novel synthetic chalcone derivatives as anti-tumor agents targeting Cat L and Cat K. |
| AID1545139 | Inhibition of cathepsin B (unknown origin) assessed as reduction in 7-amino-4-methylcoumarin formation using Z-Arg-Arg-MCA as substrate preincubated for 3 mins followed by substrate addition and measured after 10 mins by fluorescence spectrometric method | 2019 | Bioorganic & medicinal chemistry, 01-01, Volume: 27, Issue:1
| Cathepsin B: Active site mapping with peptidic substrates and inhibitors. |
| AID723745 | Inhibition of human MCF10A neoT cell invasion expressing c-Ha-Ras oncogene at 5 uM after 30 mins relative to DMSO-treated control | 2013 | Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2
| Development of new cathepsin B inhibitors: combining bioisosteric replacements and structure-based design to explore the structure-activity relationships of nitroxoline derivatives. |
| AID1712999 | Inhibition of cathepsin L (unknown origin) using Z-FR-AMC as substrate preincubated for 30 mins followed by substrate addition and further incubated for 30 mins under shaking condition by fluorescence assay | 2016 | European journal of medicinal chemistry, Oct-04, Volume: 121 | Neuroprotective effect of synthetic chalcone derivatives as competitive dual inhibitors against μ-calpain and cathepsin B through the downregulation of tau phosphorylation and insoluble Aβ peptide formation. |
| AID350740 | Inhibition of human liver cathepsin D after 30 mins by fluorometric end-point assay | 2009 | Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
| Identification of 3-acetyl-2-aminoquinolin-4-one as a novel, nonpeptidic scaffold for specific calpain inhibitory activity. |
| AID1390137 | Antiinvasive activity against human MCF10AneoT cells at 5 uM incubated for 1 hr measured every 15 mins for 72 hrs by real time xCELLigence assay relative to control | 2018 | Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
| Cathepsin B inhibitors: Further exploration of the nitroxoline core. |
| AID350738 | Inhibition of human liver cathepsin L after 30 mins by fluorometric end-point assay | 2009 | Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
| Identification of 3-acetyl-2-aminoquinolin-4-one as a novel, nonpeptidic scaffold for specific calpain inhibitory activity. |
| AID1713008 | Inhibition of cathepsin B in human SH-SY5Y cells using RR-AMC as substrate by fluorescence microplate reader assay | 2016 | European journal of medicinal chemistry, Oct-04, Volume: 121 | Neuroprotective effect of synthetic chalcone derivatives as competitive dual inhibitors against μ-calpain and cathepsin B through the downregulation of tau phosphorylation and insoluble Aβ peptide formation. |
| AID1712997 | Inhibition of human erythrocytes mu-calpain using Pep1 as substrate incubated for 30 mins under shaking condition in presence of CaCl2 by fluorescence assay | 2016 | European journal of medicinal chemistry, Oct-04, Volume: 121 | Neuroprotective effect of synthetic chalcone derivatives as competitive dual inhibitors against μ-calpain and cathepsin B through the downregulation of tau phosphorylation and insoluble Aβ peptide formation. |
| AID350739 | Inhibition of human liver cathepsin H after 30 mins by fluorometric end-point assay | 2009 | Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
| Identification of 3-acetyl-2-aminoquinolin-4-one as a novel, nonpeptidic scaffold for specific calpain inhibitory activity. |
| AID1390127 | Inhibition of cathepsin B in human MCF-10A neoT cells assessed as proteolysis of extracellular membrane by measuring decrease in intracellular degradation of DQ-collagen 4 at 50 uM incubated for 2 hrs followed by DQ-collagen addition measured for 2 hrs by | 2018 | Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
| Cathepsin B inhibitors: Further exploration of the nitroxoline core. |
| AID1800261 | Cathepsin B Inhibition Assay from Article 10.1016/j.bioorg.2013.09.002: \\Synthesis and investigation of dihydroxychalcones as calpain and cathepsin inhibitors.\\ | 2013 | Bioorganic chemistry, Dec, Volume: 51 | Synthesis and investigation of dihydroxychalcones as calpain and cathepsin inhibitors. |
| AID1800260 | m-Calpain Inhibition Assay from Article 10.1016/j.bioorg.2013.09.002: \\Synthesis and investigation of dihydroxychalcones as calpain and cathepsin inhibitors.\\ | 2013 | Bioorganic chemistry, Dec, Volume: 51 | Synthesis and investigation of dihydroxychalcones as calpain and cathepsin inhibitors. |
| AID1800259 | µ-Calpain Inhibition Assay from Article 10.1016/j.bioorg.2013.09.002: \\Synthesis and investigation of dihydroxychalcones as calpain and cathepsin inhibitors.\\ | 2013 | Bioorganic chemistry, Dec, Volume: 51 | Synthesis and investigation of dihydroxychalcones as calpain and cathepsin inhibitors. |
| AID1797510 | Inhibitory Activity Measurement of Bovine Cathepsin B. from Article 10.1016/j.jmb.2006.07.070: \\Quantitative evaluation of each catalytic subsite of cathepsin B for inhibitory activity based on inhibitory activity-binding mode relationship of epoxysucciny | 2006 | Journal of molecular biology, Oct-06, Volume: 362, Issue:5
| Quantitative evaluation of each catalytic subsite of cathepsin B for inhibitory activity based on inhibitory activity-binding mode relationship of epoxysuccinyl inhibitors by X-ray crystal structure analyses of complexes. |
| AID1800262 | Cathepsin L Inhibition Assay from Article 10.1016/j.bioorg.2013.09.002: \\Synthesis and investigation of dihydroxychalcones as calpain and cathepsin inhibitors.\\ | 2013 | Bioorganic chemistry, Dec, Volume: 51 | Synthesis and investigation of dihydroxychalcones as calpain and cathepsin inhibitors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |